display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HR positive
es-BC - HR-positive - 1st line (L1)
phosphoinositide 3-kinase (PI3K) inhibitor
taselisib based treatment
taselisib plus letrozole LORELEI

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons